{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:40:32Z","timestamp":1758750032125,"version":"3.44.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00198-025-07638-3","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T21:19:42Z","timestamp":1753391982000},"page":"1767-1769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Zoledronic acid-induced acute psychiatric disorder"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9905-128X","authenticated-orcid":false,"given":"Ya-Jun","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Qun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"7638_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40265-016-0662-4","volume":"76","author":"S Dhillon","year":"2016","unstructured":"Dhillon S (2016) Zoledronic acid (Reclast\u00ae, Aclasta\u00ae): a review in osteoporosis. Drugs 76:1683\u20131697","journal-title":"Drugs"},{"key":"7638_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL et al (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317:48\u201358","journal-title":"JAMA"},{"key":"7638_CR3","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/S0960-9776(03)80160-1","volume":"12","author":"D Cameron","year":"2003","unstructured":"Cameron D (2003) Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. Breast 12:S22\u2013S29","journal-title":"Breast"},{"key":"7638_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"7638_CR5","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/annonc\/mdh478","volume":"15","author":"G Ferretti","year":"2004","unstructured":"Ferretti G, Petti MC, Carlini P et al (2004) Zoledronic acid-associated thrombotic thrombocytopenic purpura. Ann Oncol 15:1847\u20131848","journal-title":"Ann Oncol"},{"key":"7638_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ophtha.2020.09.041","volume":"128","author":"C Provost","year":"2021","unstructured":"Provost C, Sen\u00e9 T, Lecler A (2021) Bisphosphonate-induced Posterior Scleritis. Ophthalmology 128:371","journal-title":"Ophthalmology"},{"key":"7638_CR7","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00198-023-06831-6","volume":"34","author":"S Karpuz","year":"2023","unstructured":"Karpuz S (2023) Zoledronic acid-induced severe lymphopenia. Osteoporos Int 34:1653\u20131655","journal-title":"Osteoporos Int"},{"key":"7638_CR8","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380\u20134387","journal-title":"J Clin Endocrinol Metab"},{"key":"7638_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.leu.2403693","volume":"19","author":"S Mariani","year":"2005","unstructured":"Mariani S, Muraro M, Pantaleoni F et al (2005) Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19:664\u2013670","journal-title":"Leukemia"},{"key":"7638_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00198-020-05653-0","volume":"32","author":"FP Chen","year":"2021","unstructured":"Chen FP, Fu TS, Lin YC, Lin YJ (2021) Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion. Osteoporos Int 32:663\u2013670","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07638-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07638-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07638-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:03:14Z","timestamp":1758747794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07638-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7638"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07638-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient in this manuscript has given written informed consent to publication of her case details.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}